about
Phylogeny of Zika Virus in Western Hemisphere, 2015Chikungunya Fever Cases Identified in the Veterans Health Administration System, 2014Influenza treatment and prophylaxis with neuraminidase inhibitors: a reviewImpact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic TestingA vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsResults of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trialDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesThe VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) studyDengue, Chikungunya & Zika Virus in VA Caribbean HCS, Nov. 2015-Aug. 2016Combining surveillance systems: effective merging of U.S. Veteran and military health data.Pharmacokinetics and tolerability of oseltamivir combined with probenecid.Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature.Effective detection of the 2009 H1N1 influenza pandemic in U.S. Veterans Affairs medical centers using a national electronic biosurveillance systemDengue surveillance in Veterans Affairs healthcare facilities, 2007-2010Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitroAcute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patientsEnhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application.Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesDecreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissueIntegrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trialHepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virusRole of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations.Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewImmune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.HIV-1 RNA and viral load.Accuracy of the TRUGENE HIV-1 genotyping kit.One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System.Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisSuccessful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review.MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.Ultrasensitive detection of rare mutations using next-generation targeted resequencing.Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012.Health-related quality of life assessment after antiretroviral therapy: a review of the literature.HIV testing of at risk patients in a large integrated health care system.Acute cardiac injury events ≤30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010-2012.Application of a non-amplification-based technology to detect invasive fungal pathogens.
P50
Q24047862-0CCA2EC7-A3D0-4954-8E26-E4976CC630DAQ24701802-DE6C0B18-6D82-44E7-B852-8E2448C990B0Q26860032-F0CB308B-7404-4EAE-89C0-0CF14D32A428Q27473086-2BF75B8A-A1C8-4F01-9D18-3576E4F07740Q27488389-29D41D80-A281-4D00-A293-820D0E456E95Q28254168-7BE712E1-B569-498E-86CB-8D9F6ED00467Q28477586-C340428C-1377-431F-A17F-F8D49F3D23E9Q28481393-39A702B6-5771-427E-B04E-7B9074B7DE90Q28483820-EBD9711A-E33C-42CA-82EA-73C2E233D204Q28488762-4060BA33-3737-4CEE-AAE8-4CFB338CC9FBQ28541478-0D740569-F598-48A1-8CF5-2632086E46F2Q30250885-35D1640E-1704-4115-8DA2-BF6C833217F9Q30357479-E2B41E24-381A-482B-9ACF-58EEC3D8CE28Q30370031-3D19D8BC-AB0B-4ADF-A56C-D00DFBE4F3A0Q30379316-2FD5373D-3105-41F0-A473-908398E5B854Q30386382-8A7474C4-C0EA-4EF4-8401-D90A1E7334A7Q33406567-55C6CDAC-A671-4F66-A951-D15530C6D802Q33635101-24DC3329-6151-4AED-80F0-B57BB87BDD15Q34022134-E1A1B5DA-CE4C-4E7E-9B55-35FF980C6AE8Q34022373-54D342A1-FB87-4485-8CF7-16D0DEEF2C4EQ34075725-615B9975-5DF6-4469-82BC-79E9EB778264Q34151052-EDEFEE8E-429A-4E17-89F7-2F32F7FDF786Q34176667-0D3230FA-870F-4898-9D10-C70A82B92592Q34445308-F4796E37-4075-40D3-834F-B6991200D792Q34545969-4ADB93A8-3FC4-4BA0-8C15-609BD8606017Q34636902-F7DA0CC9-8498-439B-B4C5-E4084D4CA834Q34651525-744E9399-4196-4A67-BFB4-3165B999211DQ34673075-1F7DD624-6140-4DA0-97A3-B87695AE44DFQ34875958-7DD362B9-4439-496B-9199-FC8A2E408629Q34972796-522E3009-1CAE-46A0-B76D-28E73A765173Q34984823-2C48DED6-FCBD-4518-94D7-C5FC0AABBD3EQ35037688-CC43C063-4BFC-4A0C-8827-678D558458D8Q35101827-BB0887C0-AE2E-4616-B89B-4C19D6E98077Q35202304-111F9FE8-ED45-446B-BC2F-B25337B6388BQ35633682-4A9220C2-D1BC-4D02-A994-6DC6582D1439Q35634390-4F3E596C-6ADB-4BCB-87A5-C6F9B68519F1Q35664740-AB29D1F0-4E2E-4AB6-8B01-5F08C17FE599Q35683072-C02FE702-40B8-4FEA-8976-9027872B1DA7Q35793997-0DF0C864-5F3E-4504-A7EF-B47C69470610Q36093358-C9C73FD2-E625-4986-A0BF-56B81816D216
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Mark Holodniy
@ast
Mark Holodniy
@en
Mark Holodniy
@es
Mark Holodniy
@nl
Mark Holodniy
@sl
type
label
Mark Holodniy
@ast
Mark Holodniy
@en
Mark Holodniy
@es
Mark Holodniy
@nl
Mark Holodniy
@sl
prefLabel
Mark Holodniy
@ast
Mark Holodniy
@en
Mark Holodniy
@es
Mark Holodniy
@nl
Mark Holodniy
@sl
P1006
P214
P1006
P106
P1153
7004800293
P21
P214
P31
P496
0000-0002-6655-7982
P735
P7859
viaf-287163734